UPSTREAM BIO, INC. Investment Income, Interest
UPSTREAM BIO, INC. (UPB) reported Investment Income, Interest of $2.66 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement › Other Income
us-gaap:InvestmentIncomeInterest · last filed 2026-08-11
- UPSTREAM BIO, INC. investment income, interest for the quarter ending 2026-06-30 was $2.66M, a 39.99% decline year-over-year.
- UPSTREAM BIO, INC. investment income, interest for the quarter ending 2026-03-31 was $3.05M, a 35.61% decline year-over-year.
- UPSTREAM BIO, INC. investment income, interest for the quarter ending 2025-12-31 was $3.65M, a 28.01% decline year-over-year.
- UPSTREAM BIO, INC. investment income, interest for the quarter ending 2025-09-30 was $4.11M, a 41.36% increase year-over-year.
- UPSTREAM BIO, INC. investment income, interest for fiscal 2025 was $16.93M, a 39.68% increase from fiscal 2024.
- UPSTREAM BIO, INC. investment income, interest for fiscal 2024 was $12.12M, a 191.07% increase from fiscal 2023.
- UPSTREAM BIO, INC. investment income, interest for fiscal 2023 was $4.17M.
| Period end | Investment Income, Interest 3 month | Investment Income, Interest 6 month | Investment Income, Interest 9 month | Investment Income, Interest 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.66M 10-Q · filed 2026-08-11 | $5.71M 10-Q · filed 2026-08-11 | $9.37M derived: sum of 3 quarters · filed 2026-08-11 | $13.47M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $3.05M 10-Q · filed 2026-05-13 | $6.71M derived: sum of 2 quarters · filed 2026-05-13 | $10.81M derived: sum of 3 quarters · filed 2026-05-13 | $15.24M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $3.65M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $7.76M derived: sum of 2 quarters · filed 2026-03-26 | $12.19M derived: sum of 3 quarters · filed 2026-08-11 | $16.93M 10-K · filed 2026-03-26 |
| 2025-09-30 | $4.11M 10-Q · filed 2025-11-05 | $8.54M derived: sum of 2 quarters · filed 2026-08-11 | $13.28M 10-Q · filed 2025-11-05 | $18.36M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $4.43M 10-Q · filed 2026-08-11 | $9.17M 10-Q · filed 2026-08-11 | $14.25M derived: sum of 3 quarters · filed 2026-08-11 | $17.15M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $4.74M 10-Q · filed 2026-05-13 | $9.82M derived: sum of 2 quarters · filed 2026-05-13 | $12.72M derived: sum of 3 quarters · filed 2026-05-13 | $15.60M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $5.08M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $7.98M derived: sum of 2 quarters · filed 2026-03-26 | $10.86M derived: sum of 3 quarters · filed 2026-03-26 | $12.12M 10-K · filed 2026-03-26 |
| 2024-09-30 | $2.90M 10-Q · filed 2025-11-05 | $5.78M derived: sum of 2 quarters · filed 2025-11-05 | $7.05M 10-Q · filed 2025-11-05 | $8.57M derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | $2.88M 10-Q · filed 2025-08-06 | $4.14M 10-Q · filed 2025-08-06 | $5.66M derived: sum of 3 quarters · filed 2025-08-06 | $7.19M derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | $1.27M 10-Q · filed 2025-05-06 | $2.79M derived: sum of 2 quarters · filed 2025-05-06 | $4.31M derived: sum of 3 quarters · filed 2025-05-06 | |
| 2023-12-31 | $1.52M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-12 | $3.05M derived: sum of 2 quarters · filed 2025-03-12 | $4.17M 10-K · filed 2025-03-12 | |
| 2023-09-30 | $1.53M 10-Q · filed 2024-11-07 | $2.65M 10-Q · filed 2024-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |